Sonnet BioTherapeutics Holdings is a company developing biologic medicines for treating oncology patients. They've developed a fully human albumin binding technology that utilizes human single chain antibodies to transport target tissues. Their lead candidates are SON-1010 and SON-080 for the treatment of non-small cell lung cancer, head and neck cancer, and chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy respectively.